Meeting: 2017 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5002 Citation: J Clin Oncol 35, 2017 (suppl; abstr 5002) Authors: Kim N. Chi, Matti Annala, Katherine Sunderland, et al. Background: ABI and ENZ are indicated as 1st line therapy for mCRPC but have not been directly compared. Optimal...
Pro zobrazení tohoto obsahu je třeba být přihlášen.